BACKGROUND/AIMS: Despite improvements in chemotherapy and surgical techniques, the prognosis in advanced @entity356 with peritoneal dissemination still remains very poor. At present, no standard method of treatment has been established for these @entity1 . Therefore, we assessed the feasibility of @entity11730 , a novel oral derivative of @entity1487 , as a postoperative adjuvant chemotherapy for these @entity1 . METHODOLOGY: Seven @entity1 were enrolled for 1 year. All @entity1 underwent macroscopically curative resection (R1) by an aggressive cytoreductive surgery. @entity11730 was given orally at a dose of 80 mg/m2/day, for 28 consecutive days followed by a 14-day rest, repeated every 6 weeks. RESULTS: @entity11730 was administered for 1 year in 3 out of 7 @entity1 , while the treatment was discontinued in 4 @entity1 due to disease progression. The median @entity11730 1 cycle given was 5. Grade 2 @entity1431 was observed in 3 @entity1 and grade 2 elevation of total @entity648 in one @entity1 . All other adverse reactions were grade 1. The median overall survival was > 696 days with a 1-year survival rate of 85.7%. The median overall progression-free survival was 213 days. CONCLUSIONS: @entity11730 is feasible as a postoperative adjuvant chemotherapy for resectable @entity356 with peritoneal seeding.

Feasibility study of XXXX for resectable @entity356 with peritoneal seeding.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity11730 :: ('5707', 'Gene') :: ['S-1'] @entity648 :: ('MESH:D001663', 'Chemical') :: ['bilirubin'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']
@entity11730 :: (5707,Gene) :: ['S-1']
